Clinical Trials Browser

DT2216 × Clear all

NCT06620302 2026-02-24

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT06964009 2026-01-08

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms

NCT04886622 2025-04-16

A Study of DT2216 in Relapsed/Refractory Malignancies

Phase 1 Completed

Other hematologic neoplasm

Hematologic Neoplasms